UTHR vs FTI Comparison

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

TechnipFMC PLC is the key provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies. Geographically it operates in Latin America generating the maximum revenue, then Europe and Central Asia, Africa, North America, Asia Pacific and Middle East.